(Q51107700)

30 March 2018

title

Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. (English)

1 reference

30 March 2018

1 reference

3

Daniel Ansari

1 reference

30 March 2018

author name string

Carlos Urey

1

1 reference

30 March 2018

Bodil Andersson

2

1 reference

30 March 2018

Agata Sasor

4

1 reference

30 March 2018

Katarzyna Said-Hilmersson

5

1 reference

30 March 2018

Johan Nilsson

6

1 reference

30 March 2018

Roland Andersson

7

1 reference

30 March 2018

publication date

15 February 2017

1 reference

30 March 2018

Scandinavian Journal of Gastroenterology

published in

1 reference

30 March 2018

volume

52

1 reference

30 March 2018

issue

5

1 reference

30 March 2018

page(s)

595-600

1 reference

30 March 2018

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Gemcitabine: a pharmacologic and clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Gemcitabine resistance in pancreatic cancer: picking the key players

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Mucins in pancreatic cancer and its microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Mucins in cancer: function, prognosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Mucins and pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Structure and function of the cell surface (tethered) mucins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Expression of MUC apomucins in normal pancreas and pancreatic tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Expression of mucin antigens in human cancers and its relationship with malignancy potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Transmembrane mucins as novel therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365521.2017.1290134

10.1080/00365521.2017.1290134

21 January 2018

Identifiers

DOI

1 reference

30 March 2018

1 reference

30 March 2018